Analysts fell to the sidelines weighing in on Universal Health (UHS – Research Report), Laboratory (LH – Research Report) and Bristol-Myers Squibb (BMY – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Universal Health (UHS)
Barclays analyst Andrew Mok CFA maintained a Hold rating on Universal Health today and set a price target of $189.00. The company’s shares closed last Thursday at $165.10.
According to TipRanks.com, CFA is a 1-star analyst with an average return of
Currently, the analyst consensus on Universal Health is a Moderate Buy with an average price target of $187.92, which is a 7.4% upside from current levels. In a report released yesterday, Stephens also maintained a Hold rating on the stock with a $185.00 price target.
See the top stocks recommended by analysts >>
Laboratory (LH)
In a report released today, Stephanie Davis from Barclays maintained a Hold rating on Laboratory, with a price target of $213.00. The company’s shares closed last Thursday at $198.35, close to its 52-week low of $195.01.
According to TipRanks.com, Davis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Laboratory has an analyst consensus of Moderate Buy, with a price target consensus of $241.22.
Bristol-Myers Squibb (BMY)
Barclays analyst Carter Gould maintained a Hold rating on Bristol-Myers Squibb today and set a price target of $43.00. The company’s shares closed last Thursday at $44.70, close to its 52-week low of $44.37.
According to TipRanks.com, Gould is a 4-star analyst with an average return of
Currently, the analyst consensus on Bristol-Myers Squibb is a Hold with an average price target of $53.86, implying a 13.7% upside from current levels. In a report issued on April 17, Wells Fargo also maintained a Hold rating on the stock with a $52.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on UHS:
- Universal Health reports Q1 adjusted EPS $3.70 vs. $2.34 last year
- UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES 2024 FIRST QUARTER FINANCIAL RESULTS
- Universal Health reports Q1 adjusted EPS $3.70, consensus $3.16
- Notable companies reporting after market close
- UHS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
